241 related articles for article (PubMed ID: 16719541)
1. Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.
Shilbayeh S; Tutunji MF
Clin Pharmacokinet; 2006; 45(6):593-610. PubMed ID: 16719541
[TBL] [Abstract][Full Text] [Related]
2. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
3. Variable omeprazole kinetics in healthy Jordanian adults.
Albsoul-Younes A; Tayyem R; Najib N
Biopharm Drug Dispos; 2005 Jul; 26(5):183-8. PubMed ID: 15906422
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole disposition in children following single-dose administration.
Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
Hu YR; Qiao HL; Kan QC
Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
[TBL] [Abstract][Full Text] [Related]
7. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
[TBL] [Abstract][Full Text] [Related]
8. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
[TBL] [Abstract][Full Text] [Related]
9. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
Ahmad L; Iqbal Z; Shah Y; Nazir S; Khan A; Khan MI; Khan A; Khuda F; Khan I
Pak J Pharm Sci; 2018 Jul; 31(4):1363-1374. PubMed ID: 30033421
[TBL] [Abstract][Full Text] [Related]
11. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
12. The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube.
Podilsky G; Berger-Gryllaki M; Testa B; Buclin T; Roulet M; Pannatier A
Eur J Clin Pharmacol; 2009 May; 65(5):435-42. PubMed ID: 19189088
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects.
Andersson T; Regårdh CG; Lou YC; Zhang Y; Dahl ML; Bertilsson L
Pharmacogenetics; 1992 Feb; 2(1):25-31. PubMed ID: 1302040
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.
Lin S; Nikanjam M; Capparelli EV; Allegrini A; Pavone D; Yim DS; Hammami MM; Bertino JS; Nafziger AN; Park YS; Kang JS; Yin OQ; Ma JD
Ther Drug Monit; 2018 Dec; 40(6):754-758. PubMed ID: 30045358
[TBL] [Abstract][Full Text] [Related]
15. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
[TBL] [Abstract][Full Text] [Related]
17. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral omeprazole in llamas.
Poulsen KP; Smith GW; Davis JL; Papich MG
J Vet Pharmacol Ther; 2005 Dec; 28(6):539-43. PubMed ID: 16343286
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule.
Schaltenbrand R; Huber R; Cotoraci CA; Mascher H; Potthast H; Hole U
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):453-9. PubMed ID: 11680670
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
